✦ LIBER ✦

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

✍ Scribed by Kantarjian, Hagop; Giles, Francis; Wunderle, Lydia; Bhalla, Kapil; O'Brien, Susan; Wassmann, Barbara; Tanaka, Chiaki; Manley, Paul; Rae, Patricia; Mietlowski, William

Book ID: 111980273
Publisher: Massachusetts Medical Society
Year: 2006
Tongue: English
Weight: 186 KB
Volume: 354
Category: Article
ISSN: 0096-6762
DOI: 10.1056/nejmoa055104

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib, nilotinib effective for imati

Dasatinib, nilotinib effective for imatinib-resistant CML and ALL

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Dasatinib in Imatinib-Resistant Philadel

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

✍ Talpaz, Moshe; Shah, Neil P.; Kantarjian, Hagop; Donato, Nicholas; Nicoll, John; 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 443 KB

Imatinib effective against residual dise

Imatinib effective against residual disease in paediatric Philadelphia chromosome-positive CML

📂 Article 📅 2004 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Nilotinib monotherapy induced complete r

Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib

✍ Sekimizu, Masahiro; Yamashita, Yuka; Ueki, Hideaki; Akita, Nobuhiro; Hattori, Hi 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 109 KB

Nilotinib in the Post-Imatinib Era for t

Nilotinib in the Post-Imatinib Era for the Treatment of Philadelphia Chromosome–Positive Leukemias

✍ Mughal, Tariq I. 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 85 KB

Associations between imatinib resistance

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

✍ Susanne Schnittger; Ulrike Bacher; Frank Dicker; Wolfgang Kern; Tamara Alpermann 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

## Abstract In patients with chronic myeloid leukemia (CML), resistance against imatinib is associated with mutations in the kinase domain (KD) of the __BCR‐ABL1__ fusion gene and/or with additional chromosomal abnormalities (ACAs) secondary to the Philadelphia chromosome. To evaluate associations